Boosh Plant-Based Brands Corporate Update |

Boosh Plant-Based Brands Inc.(CSE: VEGI) (OTCQB: VGGIF) (FSE: 77i) ("Boosh" or the "Company") a premier plant-based brand in the "better for you" food sector, provides the following corporate update.

The Company reports that: (i) there are no changes to the information contained in the bi-weekly status updated dated August 2, 2022, that would reasonably be expected to be material to an investor; (ii) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Documents is continuing, each of which will be issued in the form of a press release; (iii) there has not been any other specified default by the Company under NP 12-203, and, except as set forth below, no such other default is anticipated; (iv) the Company is not subject to any insolvency proceedings; and (v) there is no material information concerning the affairs of the Company that has not been generally disclosed.

The Company continues to work with its auditors to complete the audit of the Company's consolidated financial statements and expects to file the Documents by August 31, 2022. The delays primarily result from the close proximity of the Company's acquisition of substantially all of the assets of Beanfields, Inc. on February 16, 2022 and the Company's financial year end of March 31 and the work required to consolidate those operations.

Connie Marples Founder/President connie@booshfood.com

About Boosh Plant-Based Brands Inc.:

Boosh Plant-Based Brands Inc., through its wholly owned subsidiary, Boosh Food (www.booshfood.com), offers high quality, non-GMO, gluten free, 100% plant-based nutritional comfort foods for the whole family. Through a separate subsidiary, Beautiful Beanfields, the Company owns Beanfields, a plant-based chips brand sold in over 7,000 stores throughout North America. Boosh, good for you and good for planet earth.

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward-looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the Company's expectations concerning the size of the Financing, its ability to close the Financing in whole or in part or at all and its plan for the proceeds of the Financing. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Click here to connect with Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77i) to receive an Investor Presentationto receive an Investor Presentation

Analysts project the plant-based meat market has the potential to grow by US$7.21 billion by 2025, with the market’s growth potential to accelerate at a CAGR of 25.14 percent. Consumers and national governing bodies have seen the appeal of more sustainable, plant-based meat alternatives as a long-term food production solution. Put in your source for the above stats

Canada, a global leader in plant protein, has invested over C$950 million in its SuperCluster initiative, with Protein Industries Canada standing as one of five sector recipients of that investment. With rapid popularity in plant-based food alternatives, investors could see exceptional early economic upside in these emerging markets across North America and the rest of the world.

Boosh Plant-Based Brands (CSE:VEGI, OTCQB:VGGIF, FSE: 77I) is a plant-based ready-to-eat food company that distributes and sells plant-based fresh-frozen meals to grocery outlets and independent grocery stores throughout Canada. Founded in 2017 in Vancouver, British Columbia, the company aims to become a leader in delivering plant-based meals, which are sustainably packaged, convenient and tasty for complete customer satisfaction.

Boosh offers an award-winning product line featuring six fresh-frozen “Heat’n Eat” meals, including entrees for one, two and “Booch Pouches,” which are easy-warmed and hearty stews and sauces.

Boosh also provides a fuller range of competitive perks compared to other plant-based competitors. All Boosh meals are 100 percent plant-based, gluten-free, dairy-free and non-GMO. Likewise, the Canadian-based company offers complete composed dishes and two different meal sizes to satisfy individual and family dining wants.

The company has a highly strategic branding supply alliance with Beyond Meat®, one of the leading plant-based meat companies on the market. Numerous benefits have developed from this relationship including utilizing Beyond Meat® in two of Boosh’s dishs, as well as allowing Boosh to market both companies on Boosh packages, which significantly expands brand awareness for both notable companies.

In late 2020, UNFI, one of the largest natural food distributors in North America, began expanding Boosh distribution throughout Canada to over 300 locations and growing. Consumers can find Boosh meals in their local grocery and big box stores like Whole Foods Market, Metro, IGA, Safeway, SPUD.ca and more. With a strong in-store and online presence, Boosh gains exposure across multiple demographics at competitive price points.

The next steps for the company include the exciting launch of Boosh Pouches across grocery outlets in the Summer of 2021, which would introduce new offerings like Sloppy Joes, Mushroom Gravy and Chili. Also, Boosh intends to prepare for its expansion into US markets and roll out a more comprehensive commercial strategy targeting lifestyle channels in the Fall.

Boosh entered into an Asset Purchase Agreement with Saltspring Harvest to acquire the assets comprising Saltspring Harvest’s business. Founded in 2016 by Chef Zoe Currelly, Saltspring Harvest was formed to prove a plant-basprotein-richrich alternatives to meat and dairy focused pâtés and spreads.

With its established 8,500 square foot multi-use facility, the company expects to create extensive promotional content and educational material on the benefits of plant-based lifestyles, which will aid its introduction to new markets.

The Boosh ecosystem is a highly curated chain containing avenues of sourcing, product development, creative direction, distribution and retail store commercialization. With leading executives and industry greats like Boosh’s president, director and founder, Connie Marples, the company is primed for exceptional growth potential and economic success across its expansion plans.

Its “Boosh Bowls for One,” offers a delicious range of meals across a wide set of cuisines like Veggie Bolognese, Mac & Cheeze & Peas, Coconut Curry Cauli, Mexican Fiesta. Additionally, its line of entrees for two offer bigger portions of crowd favorites like Rustic Veggie Pot Pit and award winning Hearty Sheperd’s Pie.

These 100 percent plant-based products contain no dairy, gluten, artificial colors and flavors and are non-GMO. Aimed to attract a wide audience of potential consumers, Boosh Bowls offer competitive pricing, sustainable and fully recyclable packaging and an exceptional plant-based alternative to crowd-favorites.

Boosh’s newest plant-based offering is its Boosh Pouches which are a uniquely delicious line of three “Heat’n Eat” dishes, which include Chili, Mushroom Good Gravy and Sloppy Joe. The company is to begin production on July 30th, 2021 and the products will be distributed in Canada through UNFI.

Connie Marples is a seasoned executive and entrepreneur with an emphasis on the food and beverage industry. She has held several senior management positions in sales, promotions, marketing and fine dining. In 2003, Marples opened Vintropolis, a Vancouver-based wine bar and bistro/VQA Wine Store and in 2005 Vintropolis received the coveted position of being on the list of Condé Nast Traveller’s Best New Restaurants in the World. She also launched Okanagan Experience, an Entertainment style fundraising coupon book in Kelowna which was later sold to “Entertainment Book”.

As a sales representative, Marples helped launch New York Seltzer, oversaw corporate travel accounts such as the Vancouver Canucks, as well as managed grocery vendor programs and promotional departments at numerous large grocery retailers and radio stations. In the fall of 2020, She won the 2020 BC Food & Beverage Rising Star Award for her development and expansion of Boosh Food. She has expanded Boosh Food into a nationally recognized plant-food brand in Canada where Boosh can be found in over 150 major food retail stores and independent grocers.

Jim Pakulis has over three decades of experience working with public and private entrepreneurial companies in a variety of emerging sectors. He is the former founder, CEO and chairman of TransCanna Holdings Inc., which through his initiative and execution acquired one of the largest vertically integrated cannabis-focused facilities in California. Pakulis has been in senior management positions for numerous publicly traded entities including CEO and chairman of General Cannabis, Inc. which from 2010 to 2012 wholly-owned Weedmaps. He oversaw the growth of General Cannabis from zero to over CAD$16-million in annual revenue.

Maria is a Chartered Professional Accountant with sound financial reporting, assurance and tax experience obtained from various roles in public accounting firms. In addition to being CFO of Boosh, she is a financial reporting manager at an accounting advisory practice where she works closely with various publicly traded companies in several industries.

Mr. Richardson has an extensive background assisting emerging growth companies in numerous industries including the plant-based food sector. Mr. Richardson has experience as an investor, executive and founder of multiple technology companies. He is a proponent and defender for sustainability as well as the environment and is an Advisory Board member to several innovative green technology companies, as well as serving as a Director for GreenPower Motor Company.

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77i) ("Boosh" or the "Company") announces that it has entered into a settlement agreement with an arm's length third party for the settlement of $191,428.52 in debt for services previously provided through the issuance of 1,519,274 common shares at a deemed price of $$0.126 per share.

All securities issued in the debt settlement are subject to a four month and one day hold period expiring on December 04, 2022.

Boosh Plant-Based Brands continues its strong sales trajectory across Canada and the US with its premiere brand of better for you chips Beanfields, Boosh ready to eat meals and Amuse boosh vegan cheese and pate.

On behalf of the Board of Directors

Connie Marples Founder/Chief Executive Officer connie@booshfood.com

About Boosh Plant-Based Brands Inc.:

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the Company's expectations for additional financing, its plan for the proceeds of the placement. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward -looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/133023

News Provided by Newsfile via QuoteMedia

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77i) ("Boosh" or the "Company") a premier plant-based brand in the in-health food sector, announces today that a management cease trade order was granted on August 2, 2022 (the "MCTO") by the British Columbia Securities Commission under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), as the Company anticipates delays in filing its financial statements for the year ended March 31, 2022, and the related management's discussion and analysis ("MD&A") and certifications (the "Annual Filings"). The MCTO does not affect the ability of investors who are not insiders to trade in the securities of the Company.

The Company will work with its auditors to complete the audit of the Company's consolidated financial statements and expects to file the Annual Filings by August 31, 2022. The delays are primarily the result of the close proximity of the Company's acquisition of substantially all of the assets of Beanfields, Inc. on February 16, 2022, and the Company's financial year end of March 31, and the work required to consolidate those operations.

Until the Company completes the Annual Filings, the Company will comply with the alternative information guidelines set out in National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults for issuers who have failed to comply with a specified continuous disclosure requirement within the times prescribed by applicable securities laws. The guidelines, among other things, require the Company to issue bi-weekly default status reports by way of a news release so long as the Annual Filings have not been filed.

The Company reports that: (i) there has not been any other specified default by the Company under NP 12-203, and no such default is anticipated; (ii) the Company is not subject to any insolvency proceedings; and (iii) there is no material information concerning the affairs of the Company that has not been generally disclosed.

Connie Marples Founder/President connie@booshfood.com

About Boosh Plant-Based Brands Inc.:

Boosh Plant-Based Brands Inc., through its wholly owned subsidiary, Boosh Food (www.booshfood.com), offers high quality, non-GMO, gluten free, 100% plant-based nutritional comfort foods for the whole family. Through a separate subsidiary, Beautiful Beanfields, the Company owns Beanfields, a plant-based chip brand sold in over 7,000 stores throughout North America. Boosh, good for you and good for planet earth.

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward-looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the Company's expectations concerning the size of the Financing, its ability to close the Financing in whole or in part or at all and its plan for the proceeds of the Financing. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/132781

News Provided by Newsfile via QuoteMedia

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77i) ("Boosh" or the "Company") is pleased to announce that it generated gross sales revenues of CA$897,048 in the month of June 2022. Costs of goods sold was $534,030.43 for the same month.

Boosh Founder and CEO Connie Marples states, "Now that we have fully integrated Beanfields Chips into our family of brands we are seeing a dramatic increase in our sales revenues. It is exciting to be shipping large volumes of product out to stores with reorders coming in fast and furious. We are working on continuing to scale up production to meet retailers demands."

The financial results disclosed in this press release are management prepared and have not been audited or reviewed by the Company's auditors. Unless otherwise indicated, all amounts are expressed in Canadian dollars. Past results are not a guarantee of future performance.

Boosh has also completed a non-brokered private placement generating aggregate gross proceeds of $170,000.

The Company issued 434,783 common shares (the "Shares") at a price of $0.23 per share and a further 350,000 Shares at a price of $0.20 per share generating aggregate gross proceeds of $170,000.

No finder's fees were payable. The proceeds of the placement will be utilized for general working capital including the payment of outstanding liabilities.

All securities issued in the private placement are subject to a four month and one day hold period expiring on November 6, 2022.

The Company also wishes to announce the recent resignations of Maria Hussaini and Rafael Almanzar from its board of directors and wants to thank them for their contribution.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of a U.S. person (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

On behalf of the Board of Directors

Connie Marples Founder/Chief Executive Officer connie@booshfood.com

About Boosh Plant-Based Brands Inc.:

Boosh Plant-Based Brands Inc., through its wholly owned subsidiary, Boosh Food (www.booshfood.com), offers high quality, non-GMO, gluten free, 100% plant-based nutritional comfort foods for the whole family. Through a separate subsidiary, Beautiful Beanfields, the Company owns Beanfields, a plant-based chip brand sold in over 7,000 stores throughout North America. Boosh, good for you and good for planet earth.

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward-looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the Company's expectations for additional financing, its plan for the proceeds of the placement. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/130072

News Provided by Newsfile via QuoteMedia

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77i) ("Bosh" or the "Company"), a premier plant-based brands in the in-health food sector, provides the following update summary:

Greg Gilbert has been named CFO of Beanfields and is an experienced finance leader focused on growing shareholder value as CFO for mid-stage food and beverage companies.

Greg's experience in the industry spans across start-up to multi-national strategic businesses; across dry, frozen, and fresh categories, and across all market channels, including in-depth experience scaling/incubating emerging/natural brands.

Greg has served as Chief Financial Officer of Beanfields since Q1 2020 where he led the work to optimize the business model; utilizing his depth of experience and inventiveness, to meet evolving investor needs.

West Bonebrake: Director of Operations Beanfields

(From the left to right: Wes Bonebrake, TJ Walsh, Colton Marples, and Greg Gilbert) To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/7944/128129_89302b48848df9db_002full.jpg

Boosh Plant-Based Brands Founder and CEO Connie Marples states, "I could not be more proud of our team through the successful integration of Beanfields into the Boosh Plant-based family of brands. The addition of Greg Gilbert and Wes Bonebrake to our management group has been seamless and their industry expertise plus history with Beanfields is highly valued."

On behalf of the Board of Directors

Connie Marples Founder/President connie@booshfood.com Telephone: 778 840 1700 www.Booshfood.com

About Boosh Plant-Based Brands Inc.:

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward-looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the Company's expectations concerning the size of the Financing, its ability to close the Financing in whole or in part or at all and its plan for the proceeds of the Financing.. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/128129

News Provided by Newsfile via QuoteMedia

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company") a premier plant-based brands company in the in-health food sector, is excited to announce the filing of a business acquisition report ("BAR") on the Company's SEDAR profile (www.sedar.com) in relation to its previously completed acquisition of the business of Beanfields, Inc. that occurred on February 16, 2022. Beautiful Beanfields Inc is now officially in our family of Brands.

The BAR includes audited carve out financial statements for the business of Beanfields for the year ended December 31, 2021 with unaudited comparative for the year ended December 30, 2020. The financial statements are prepared in accordance with International Financial Reporting Standards.

Beanfields produces and sells a healthy, gluten-free, non-GMO, vegan, top eight allergen-free flavored bean-based chip. The portfolio includes a broad offering of nine flavors, including Black Bean, Sour Cream and Onion, Fiery Hot and Nacho flavors. They have capitalized on the industry trends of 'Better For You' in the salty snack category. Beanfields received the 2019 "Rising Star Award" from NOSH (Natural, Organic, Sustainable and Healthy) organization. In June 2021, it introduced its Rings line, which became one of its fastest-selling products. This past December, NOSH recognized Rings as a Best New Product for 2021.

Since we acquired the Beanfields business in February, our team has been increasing production levels to meet high demands from retailers. Our first priority was to purchase large quantities of raw material to prevent supply disruption, increase production to match demand, and reach out to the current customer base - all of which has been successfully orchestrated. We've been able to maintain the vast majority of Beanfields' approximate 7,000 retailers, as we continue to stock shelves to meet customer demand. Beanfields chips are currently sold throughout all 50 states, Canada, and other countries. As can be seen in the audited carve out statements for the year ended December 31, 2021, the Beanfields brand generated Net Revenues of US$8.8M, which consisted of US$11.5M in gross sales, net of US$2.7M in sales discounts and manufacture chargebacks. We expect to continue to push sales momentum and drive further growth within the Company's full product portfolio.

On behalf of the Board of Directors

Connie Marples Founder/CEO connie@booshfood.com Telephone: 778 840 1700 www.Booshfood.com

About Boosh Plant-Based Brands Inc.:

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the Company's expectations concerning the revenue growth potential of Beanfields and its ability to generate profits there from. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/127176

News Provided by Newsfile via QuoteMedia

Gilead Will Provide $4.5 Million in Funding to Help Improve Health Outcomes for Black Americans in the Southern United States –

– Investment Reflects Gilead's Broad and Ongoing Commitment to Advancing Health Equity –

Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new health equity collaboration with the Satcher Health Leadership Institute (SHLI) at Morehouse School of Medicine and the Center for Minority Health and Health Disparities Research and Education (CMHDRE) at Xavier University of Louisiana's College of Pharmacy. The collaboration is focused on addressing the inequities in HIV care for Black communities in the Southern United States. Gilead has a broad and long-standing commitment to advancing global health equity, which it regards as critical to helping to end the HIV epidemic and improving health outcomes for all. The company's health equity strategy focuses on collaborating with organizations that reach underrepresented and disproportionately impacted communities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220816005886/en/

Research shows that inequities drive higher rates of HIV infection, as well as worse HIV clinical outcomes among Black Americans. The COVID-19 pandemic has further highlighted and exacerbated such health inequities, especially in the Southern United States. SHLI and CMHDRE are at the forefront of efforts to improve access to HIV care for Black communities in the Southern U.S. region. Gilead will award a total of $4.5 million in funding over a three-year period to support their work in three cities: Atlanta, Baton Rouge, La., and New Orleans.

The partnership between SHLI and CMHDRE, with support from Gilead, is intended to close critical gaps in care by:

"Gilead knows that scientific innovation has the most impact on patients when we help remove societal barriers to care, such as discrimination and stigma. We are committed to investing in organizations, community leaders and experts working to address the underlying determinants of health outcomes," said Rashad Burgess, Vice President of Advancing Health and Black Equity, Gilead Sciences. "This collaboration will focus on the barriers that are most prevalent in Black communities and help increase access to HIV care to produce better outcomes for Black people."

"Though the COVID-19 pandemic was a setback to the American healthcare system overall, we must bring to the forefront disproportionately impacted communities who were already historically marginalized prior to the pandemic, including people living with HIV," said Daniel E. Dawes, J.D., Executive Director, Satcher Health Leadership Institute at Morehouse School of Medicine, and author of The Political Determinants of Health. "The Satcher Health Leadership Institute will collaborate with Gilead and Xavier University of Louisiana to ensure these communities are not an afterthought."

"Xavier's Center for Minority Health and Health Disparities Research and Education in the College of Pharmacy is proud to partner with Gilead and the Satcher Health Leadership Institute at Morehouse School of Medicine for such an important initiative," said Dr. Kathleen Kennedy, Dean of Xavier University of Louisiana's College of Pharmacy. "Xavier is a top producer of African Americans with a Doctor of Pharmacy degree, and we instill in our graduates the mission of Xavier and the desire to serve the underserved with an effort to mitigate health disparities for underrepresented communities."

This latest collaboration is part of Gilead's broader health equity strategy to support community organizations across the globe in addressing social determinants of health. A recent report commissioned by Gilead, " HIV In The Time of COVID-19: Leaving No-One Behind to Truly End the HIV Epidemic ," details a broad range of barriers to health equity including social and economic factors. While predictors of health outcomes such as race, ethnicity and gender have long existed, the COVID-19 pandemic has exacerbated health inequities, especially for marginalized communities and those affected by HIV. Gilead is increasing investment to address these underlying inequities highlighted by the intersection of the two health crises.

Other Gilead programs that address health equity include the COMPASS Initiative ® , a ten-year, $100 million commitment toward addressing HIV/AIDS inequities in the U.S. South, which continues to challenge the structural barriers that are most prevalent in Black communities. Gilead's Zeroing In™ program supports communities in 41 countries that have been hit doubly hard by HIV and the COVID-19 pandemic. Gilead also created a $10 million Racial Equity Community Impact Fund to support organizations fighting the racial inequities that affect Black communities. In its most recent report, the Funders Concerned About AIDS named Gilead the number one overall philanthropic funder of HIV/AIDS programs.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead's medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative ® to community organizations that are working to combat HIV in the U.S. South. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.

About Satcher Health Leadership Institute at Morehouse School of Medicine

The Satcher Health Leadership Institute (SHLI) at Morehouse School of Medicine aims to be the leading transformational force for health equity in policy, leadership development and research. Rooted in the legacy of its founder, the 16th U.S. Surgeon General, Dr. David Satcher, SHLI's mission is to create systemic change at the intersection of policy and equity by focusing on three priority areas: the political determinants of health, health system transformation, and mental and behavioral health. In conjunction with key strategic partners, SHLI enhances leadership among diverse learners, conducts forward-thinking research on the drivers of health inequities and advances evidence-based policies, all in an effort to contribute to the achievement of health equity for all population groups. Learn more at https://satcherinstitute.org ; https://healthequitynetwork.org .

About Xavier University of Louisiana and the Center for Minority Health and Health Disparities Research and Education

Established in 1925, Xavier University of Louisiana is the nation's only historically Black and Catholic University. Located in New Orleans, La., its liberal arts-based programs in diverse fields offer students an unbeatable combination of traditional classroom study, hands-on research, service-learning opportunities and life experiences. Xavier is recognized by the United Negro College Fund (UNCF) as the most successful HBCU in terms of graduates' upward mobility (2022) and is a nationally recognized leader in STEM and the health sciences. Xavier is known for producing more African American students who graduate from medical schools each year than any other university in the country, and its College of Pharmacy is among the top producers of African American pharmacists. Visit www.xula.edu to learn more.

The Center for Minority Health and Health Disparities Research and Education (CMHDRE) within Xavier's College of Pharmacy was founded in 2004 to improve the health outcomes of racial and ethnic minorities. The CMHDRE's mission is to provide the infrastructure required to conduct research and provide community education and clinical services to eliminate health disparities using community engagement and collaborative partnerships. It conducts basic and translational research, provides culturally relevant education and clinical services in the community, and educates current and future health care providers as a forefront leader in the initiative to improve health outcomes for minority populations in the region.

Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company's website at www.gilead.com , follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800- GILEAD-5 or 1-650-574-3000.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220816005886/en/

Jareese K. Stroud, SHLI (404) 752-1907

Regi Reyes, Xavier University of Louisiana (504) 520-5240

News Provided by Business Wire via QuoteMedia

Allē Double Point Promotion Encourages Consumers to See the JUVÉDERM ® Difference

Allergan Aesthetics, an ABBVie company (NYSE: ABBV), invites consumers to experience the JUVÉDERM ® difference. The JUVÉDERM ® Collection of Fillers is the number one selling collection of dermal fillers on the market and offers the largest portfolio of fillers specifically designed for different areas of the face to address key patient concerns, enabling a customized treatment approach. 1 Injectable dermal fillers are highly sought-after treatments among consumers who are looking to address key signs of aging or to simply accentuate what is already naturally theirs.

Right now, consumers can earn double points in Allē, Allergan Aesthetics' loyalty rewards program, when treated with two or three syringes from the JUVÉDERM ® Collection of Fillers during the same visit. Allē points can be redeemed for future Allē-eligible treatments or products. The promotion runs through Friday, September 30, 2022 . Allē members can also use the Allē Flash program to determine if they are eligible for additional savings.

"We estimate that in the U.S., 20 million consumers are interested in receiving treatment with a dermal filler in the next two years. 2 We help support and grow the filler market while ensuring that all consumers who are interested in talking to their specialist about treatment with the JUVÉDERM ® Collection of Fillers have access to education and the product. Recently, we launched a YouTube channel to provide deeper patient education and it has more than five million views since launch," said Carrie Strom , Global President Allergan Aesthetics. "The JUVÉDERM ® Collection of Fillers is the number one chosen dermal filler collection in the U.S. and approved for all skin tones. 1, 3-5 We are excited to share our passion for the JUVÉDERM ® Collection of Fillers with consumers through this limited time offer. We invite them to talk to their specialist and experience the JUVÉDERM ® difference for themselves."

The JUVÉDERM ® difference is achieved with a wide range of minimally invasive treatment options that provides instant results that are long-lasting and natural-looking. 6-12 Additionally, the JUVÉDERM ® Collection of Fillers' VYCROSS ® technology is the number one chosen dermal filler technology worldwide. 1 As the number one chosen dermal filler collection worldwide, JUVÉDERM ® boasts the top chosen fillers for cheeks (JUVÉDERM ® VOLUMA ® XC), lower face wrinkles and folds (JUVÉDERM ® Ultra Plus XC and JUVÉDERM ® VOLLURE ® XC), lips (JUVÉDERM ® Ultra XC and JUVÉDERM ® VOLBELLA ® XC), and perioral lines (JUVÉDERM ® VOLBELLA ® XC). 1

"I use the full JUVÉDERM ® Collection of Fillers to achieve optimal aesthetic outcomes for my patients," said Dr. Deborah Sherman , board certified, fellowship trained ophthalmic plastic surgeon and master injector. "As one of the longest standing filler manufacturers in the industry, it's a brand I trust due to the years of clinical studies and safety data available to help me feel confident in the product I'm offering to my patients. Even the JUVÉDERM ® syringe itself is innovative – it's the first and only certified ergonomic syringe that helps minimize hand fatigue so I can comfortably treat patients all day long. JUVÉDERM ® enables me to offer my patients a suite of premium products that deliver smooth, natural-looking, and long-lasting results 6-12 so my patients keep coming back time and again."

About the JUVÉDERM ® Double Points Promotion Consumers can experience the JUVÉDERM ® difference while earning double points in Allē towards a future JUVÉDERM ® or other Allē eligible treatment when treated with two or three syringes from the JUVÉDERM ® Collection of Fillers during the same visit through Friday, September 30, 2022 . Consumers who take the challenge and experience the JUVÉDERM ® difference will be treated with products that are:

Consumers are encouraged to enroll in Allē to unlock access to the current promotion, subject to applicable program terms and conditions. Allē is the first and only loyalty program in the aesthetics market to also offer consumers the ability to earn points on over 40 non-Allergan Aesthetics treatments and brands. To learn more about Allē, visit Alle.com.

For more information on the JUVÉDERM ® Collection of Fillers, visit Juvéderm.com, follow @JUVÉDERM on Instagram and subscribe to the JUVÉDERM ® Collection of Fillers channel on YouTube.

About Allergan Aesthetics At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.AllerganAesthetics.com .

About AbbVie AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com . Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

JUVÉDERM ® Injectable Gel Fillers Important Information

JUVÉDERM ® VOLUMA ® XC injectable gel is for deep injection in the cheek area to correct age-related volume loss and for augmentation of the chin region to improve the chin profile in adults over 21.

JUVÉDERM ® VOLUX™ XC injectable gel is for deep injection to improve moderate to severe loss of jawline definition in adults over the age of 21.

JUVÉDERM ® VOLLURE ® XC, JUVÉDERM ® Ultra Plus XC, and JUVÉDERM ® Ultra XC injectable gels are for injection into the facial tissue for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. JUVÉDERM ® VOLLURE ® XC injectable gel is for adults over 21.

JUVÉDERM ® Ultra XC injectable gel is also for injection into the lips and perioral area for lip augmentation in adults over 21.

JUVÉDERM ® VOLBELLA ® XC injectable gel is indicated for injection into the lips for lip augmentation and correction of perioral lines, and for injection into the undereye hollows to improve the appearance of undereye hollows in adults over the age of 21.

Are there any reasons why I should not receive any JUVÉDERM ® formulation? Do not use these products if you have a history of multiple severe allergies or severe allergic reactions (anaphylaxis), or if you are allergic to lidocaine or the Gram-positive bacterial proteins used in these products, or if you have had previous allergic reactions to hyaluronic acid fillers.

What warnings should my doctor advise me about?

What precautions should my doctor advise me about?

What are possible side effects of treatment? The most commonly reported side effects with JUVÉDERM ® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM ® VOLBELLA ® XC, dryness was also reported.

These side effects are consistent with other facial injection procedures, and most will resolve with time. Your doctor may choose to treat side effects persisting over 30 days with antibiotics, steroids, or hyaluronidase (an enzyme that breaks down hyaluronic acid).

As with all skin injection procedures, there is a risk of infection.

To report a side effect with any product in the JUVÉDERM ® Collection, please call the Allergan ® Product Support Department at 1‑877‑345‑5372. Please also visit Juvederm.com or talk to your doctor for more information.

Products in the JUVÉDERM ® Collection are available only by a licensed physician or properly licensed practitioner.

View original content to download multimedia: https://www.prnewswire.com/news-releases/experience-the-juvederm-difference-with-allergan-aesthetics-301607369.html

News Provided by PR Newswire via QuoteMedia

Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. ("Turning Point"), in an all-cash transaction. With the completion of the acquisition, Turning Point shares have ceased trading on the NASDAQ Global Select Market and Turning Point is now a wholly owned subsidiary of Bristol Myers Squibb.

"Turning Point has distinguished itself in the field of precision oncology, and this acquisition will further strengthen our leading oncology franchise," said Elizabeth Mily, Executive Vice President, Strategy & Business Development, Bristol Myers Squibb. "With Turning Point's lead asset, repotrectinib, Bristol Myers Squibb will be positioned to address a significant unmet medical need for ROS1-positive non-small cell lung cancer patients. We look forward to bringing this promising, innovative medicine to patients in the second half of 2023."

Through the transaction, Bristol Myers Squibb gains a pipeline of investigational medicines designed to target the most common mutations associated with oncogenesis, including repotrectinib. Repotrectinib is a next-generation, potential best-in-class tyrosine kinase inhibitor targeting the ROS1 and NTRK oncogenic drivers of non-small cell lung cancer (NSCLC) and other advanced solid tumors. In the Phase 1/2 TRIDENT-1 clinical trial, longer duration of response has been observed in the landmark analysis with repotrectinib than with existing ROS1 agents in first-line NSCLC. The asset has been granted three Breakthrough Therapy Designations from the U.S. Food and Drug Administration.

Bristol Myers Squibb expects repotrectinib to be approved in the U.S. in the second half of 2023 and become a new standard of care for patients with ROS1-positive NSCLC in the first-line setting. Bristol Myers Squibb also plans to continue to explore the potential of Turning Point's promising pipeline of novel compounds.

Bristol Myers Squibb's previously announced tender offer for all outstanding shares of common stock of Turning Point for $76.00 per share expired at 5:00 p.m. Eastern Time on August 15, 2022. Approximately 41,896,678 shares of Turning Point common stock were validly tendered, and not validly withdrawn from the tender offer, representing approximately 84% of Turning Point's issued and outstanding shares of common stock. In accordance with the terms of the tender offer, all shares that were validly tendered and not validly withdrawn have been accepted for payment and Bristol Myers Squibb expects to promptly pay for all such shares.

Following completion of the tender offer, Bristol Myers Squibb completed the acquisition of Turning Point through the merger of its wholly owned subsidiary, Rhumba Merger Sub Inc., with and into Turning Point, without a vote of Turning Point's stockholders pursuant to Section 251(h) of the General Corporation Law of the State of Delaware. As a result of the merger, each share of common stock of Turning Point issued and outstanding and not tendered in the tender offer was automatically converted into the right to receive an amount in cash equal to $76.00, without interest, subject to any applicable withholding of taxes, the same price offered in the tender offer.

Turning Point shareholders can direct questions regarding the tender offer to MacKenzie Partners, Inc., the information agent for the tender offer, toll free, at 1-800-322-2885.

Gordon Dyal & Co., LLC, is serving as the exclusive financial advisor to Bristol Myers Squibb, and Kirkland & Ellis, LLP, is serving as legal counsel. Goldman Sachs & Co., LLC, is serving as the exclusive financial advisor to Turning Point Therapeutics, and Cooley, LLP, is serving as legal counsel.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

Cautionary Statement Regarding Forward-Looking Statements

This communication contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the acquisition of Turning Point by Bristol Myers Squibb. These statements may be identified by the fact they use words such as "should," "could," "expect," "anticipate," "estimate," "target," "may," "project," "guidance," "intend," "plan," "believe," "will" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. These statements are only predictions, and such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Actual results may differ materially from current expectations because of numerous risks and uncertainties including with respect to (i) the risk that the expected benefits or synergies of the acquisition will not be realized, (ii) the risk that legal proceedings may be instituted related to the merger agreement, and (iii) unanticipated difficulties or expenditures relating to the transaction, the response of business partners and competitors to the consummation of the transaction and/or potential difficulties in employee retention as a result of the consummation of the transaction. Forward-looking statements in this communication should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2021, and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and in Turning Point's Annual Report on Form 10-K for the year ended December 31, 2021 and its subsequent Quarterly Reports on Form 10-Q , as well as other documents that may be filed by Bristol Myers Squibb from time to time with the SEC. Neither Bristol Myers Squibb nor Turning Point undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. The forward-looking statements made in this communication relate only to events as of the date on which the statements are made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220817005168/en/

Media: media@bms.com Investors: investor.relations@bms.com

News Provided by Business Wire via QuoteMedia

Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) ("Turning Point") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), and the receipt of merger control clearance from the Federal Cartel Office of Germany ("FCO"), in connection with the previously announced offer (the "Offer") to acquire all outstanding shares of common stock of Turning Point at a price of $76.00 per share in an all-cash transaction for total consideration of approximately $4.1 billion. The expiration of the HSR Act waiting period occurred at 11:59 p.m. Eastern Time on August 15, 2022, and the FCO clearance was received on August 15, 2022. The Offer expired at 5:00 p.m. Eastern Time on August 15, 2022 (the "Expiration Time"), and the Offer was not extended.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220816005404/en/

Equiniti Trust Company, the depositary for the Offer, has advised that, as of the Expiration Time, approximately 41,896,678 shares of common stock were validly tendered, and not validly withdrawn pursuant to Offer, representing approximately 84% of the issued and outstanding shares of common stock.

The parties expect the transaction to close on August 17, 2022, promptly following the acceptance of all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer.

Turning Point shareholders can direct questions regarding the Offer to MacKenzie Partners, Inc., the information agent for the Offer, toll free, at 1-800-322-2885.

About Turning Point Therapeutics Inc.

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of precision oncology drug candidates is being studied across a variety of solid tumors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com .

Additional Information about the Offer and Where to Find It

This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender offer materials that Bristol Myers Squibb and Rhumba Merger Sub Inc. ("Offeror") filed with the SEC. At the time the tender offer was commenced, Bristol Myers Squibb caused Offeror to file a tender offer statement on Schedule TO and Turning Point filed a recommendation statement on Schedule 14D-9. INVESTORS AND TURNING POINT'S STOCKHOLDERS ARE STRONGLY ADVISED TO READ THE TENDER OFFER STATEMENT AND THE RELATED SOLICITATION/ RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 FILED BY TURNING POINT WITH THE SEC, AS AMENDED OR SUPPLEMENTED FROM TIME TO TIME, BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SHOULD BE CONSIDERED BY TURNING POINT'S INVESTORS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. These documents are available at no charge on the SEC's website at www.sec.gov. In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents may be obtained free of charge at www.bms.com or by directing a request to Bristol Myers Squibb, Office of the Corporate Secretary, 430 East 29th Street, 14th Floor, New York, New York 10154-0037. A copy of the tender offer statement and the solicitation/recommendation statement are made available to all stockholders of Turning Point free of charge at www.tptherapeutics.com .

In addition to the offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, Bristol Myers Squibb and Turning Point file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read any reports, statements or other information filed by Bristol Myers Squibb or Turning Point with the SEC at no charge on the SEC's website at www.sec.gov .

Cautionary Statement Regarding Forward-Looking Statements

This communication contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the acquisition of Turning Point by Bristol Myers Squibb. These statements may be identified by the fact they use words such as "should," "could," "expect," "anticipate," "estimate," "target," "may," "project," "guidance," "intend," "plan," "believe," "will" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. These statements are only predictions, and such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Actual results may differ materially from current expectations because of numerous risks and uncertainties including with respect to (i) the timing of the closing of the merger, (ii) the risk that the expected benefits or synergies of the acquisition will not be realized, (iii) the risk that legal proceedings may be instituted related to the merger agreement, and (iv) unanticipated difficulties or expenditures relating to the proposed transaction, the response of business partners and competitors to the consummation of the transaction and/or potential difficulties in employee retention as a result of the consummation of the proposed transaction. Forward-looking statements in this communication should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2021, and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and in Turning Point's Annual Report on Form 10-K for the year ended December 31, 2021 and its subsequent Quarterly Reports on Form 10-Q , as well as other documents that may be filed by Bristol Myers Squibb or Turning Point from time to time with the SEC. Neither Bristol Myers Squibb nor Turning Point undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. The forward-looking statements made in this communication relate only to events as of the date on which the statements are made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220816005404/en/

Bristol Myers Squibb Media: media@bms.com Investor Relations: investor.relations@bms.com

Turning Point Therapeutics Media and Investor Relations: ir@tptherapeutics.com

News Provided by Business Wire via QuoteMedia

Gilead will Assume Responsibility for Clinical Development and Commercialization in Greater China and South Korea, among Other Asian Markets –

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Everest Medicines to transfer all development and commercialization rights to Gilead for Trodelvy ® (sacituzumab govitecan) in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia.

In China mainland and Singapore, Trodelvy is approved for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Gilead continues to work closely with regulatory bodies in Hong Kong, South Korea and Taiwan, where New Drug Applications, filed by Everest Medicines for metastatic TNBC, are currently under review.

"Trodelvy is approved for second-line metastatic TNBC in over 35 countries. We thank Everest Medicines for their partnership and important contributions in the development of Trodelvy in Asia. Their collaboration has brought us closer to bringing Trodelvy to patients who need alternative options," said Bill Grossman, MD, PhD, Senior Vice President, Oncology Clinical Research, Gilead Sciences. "Trodelvy is the cornerstone of our solid tumor portfolio, and we are committed to bringing this transformative therapy to as many patients as possible. We look forward to rapidly advancing our development program in Asia and to realizing the clinical potential of Trodelvy across diverse tumor types."

In April 2019, Everest Medicines and Immunomedics entered into an agreement granting Everest Medicines an exclusive license to develop and commercialize Trodelvy in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia, excluding Japan. Gilead subsequently acquired Immunomedics in October 2020 and created an extensive global clinical development program, including investigating Trodelvy as a monotherapy and in novel combinations, across multiple disease areas including non-small cell lung cancer, metastatic urothelial cancer and gastrointestinal cancers.

"We welcome the opportunity to restructure our partnership with Gilead, which has been built on a shared vision of providing innovative oncology solutions for patients in need. With capital resources and a track record of successful therapeutic development and commercialization for Trodelvy in the U.S., Gilead is an ideal partner to further develop and commercialize Trodelvy in Asia Pacific regions to maximize patient access," said Kerry Blanchard, MD, PhD, Chief Executive Officer of Everest Medicines. "I am exceedingly proud of what Everest has accomplished in advancing Trodelvy in China and other Asia territories, and we will continue to bring more transformational therapies to patients in China and worldwide with our extensive pipeline of clinical and pre-clinical stage assets."

Under the terms of the agreement, Gilead will make a $280 million upfront payment to Everest. In addition, Everest is eligible to receive up to $175 million in potential additional payments upon achievement of certain regulatory and commercial milestones. Gilead will also have the opportunity to recruit Everest employees working directly on the Trodelvy program. The transaction is expected to close later this year, and will be subject to customary closing conditions, including approval by Everest's shareholders.

Trodelvy U.S. Prescribing Information has a Boxed Warning for severe or life-threatening neutropenia and severe diarrhea; see below for Important Safety Information.

Trodelvy ® (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and bladder cancers. Trodelvy is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the microenvironment.

Trodelvy is approved in over 35 countries, with multiple additional regulatory reviews underway worldwide, for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Trodelvy is also approved in the U.S. under the accelerated approval pathway for the treatment of adult patients with locally advanced or metastatic urothelial cancer (UC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.

Trodelvy is also being developed for potential investigational use in other TNBC and metastatic UC populations, as well as a range of tumor types where Trop-2 is highly expressed, including hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, metastatic non-small cell lung cancer (NSCLC), metastatic small cell lung cancer (SCLC), head and neck cancer, and endometrial cancer.

U.S. Indications for Trodelvy

In the United States, Trodelvy is indicated for the treatment of:

U.S. Important Safety Information for Trodelvy

BOXED WARNING: NEUTROPENIA AND DIARRHEA

Neutropenia: Severe, life-threatening, or fatal neutropenia can occur and may require dose modification. Neutropenia occurred in 61% of patients treated with Trodelvy. Grade 3-4 neutropenia occurred in 47% of patients. Febrile neutropenia occurred in 7%. Withhold Trodelvy for absolute neutrophil count below 1500/mm 3 on Day 1 of any cycle or neutrophil count below 1000/mm 3 on Day 8 of any cycle. Withhold Trodelvy for neutropenic fever.

Diarrhea: Diarrhea occurred in 65% of all patients treated with Trodelvy. Grade 3-4 diarrhea occurred in 12% of patients. One patient had intestinal perforation following diarrhea. Neutropenic colitis occurred in 0.5% of patients. Withhold Trodelvy for Grade 3-4 diarrhea and resume when resolved to ≤Grade 1. At onset, evaluate for infectious causes and if negative, promptly initiate loperamide, 4 mg initially followed by 2 mg with every episode of diarrhea for a maximum of 16 mg daily. Discontinue loperamide 12 hours after diarrhea resolves. Additional supportive measures (e.g., fluid and electrolyte substitution) may also be employed as clinically indicated. Patients who exhibit an excessive cholinergic response to treatment can receive appropriate premedication (e.g., atropine) for subsequent treatments.

Hypersensitivity and Infusion-Related Reactions: Serious hypersensitivity reactions including life-threatening anaphylactic reactions have occurred with Trodelvy. Severe signs and symptoms included cardiac arrest, hypotension, wheezing, angioedema, swelling, pneumonitis, and skin reactions. Hypersensitivity reactions within 24 hours of dosing occurred in 37% of patients. Grade 3-4 hypersensitivity occurred in 2% of patients. The incidence of hypersensitivity reactions leading to permanent discontinuation of Trodelvy was 0.3%. The incidence of anaphylactic reactions was 0.3%. Pre-infusion medication is recommended . Observe patients closely for hypersensitivity and infusion-related reactions during each infusion and for at least 30 minutes after completion of each infusion. Medication to treat such reactions, as well as emergency equipment, should be available for immediate use. Permanently discontinue Trodelvy for Grade 4 infusion-related reactions.

Nausea and Vomiting: Nausea occurred in 66% of all patients treated with Trodelvy and Grade 3 nausea occurred in 4% of these patients. Vomiting occurred in 39% of patients and Grade 3-4 vomiting occurred in 3% of these patients. Premedicate with a two or three drug combination regimen (e.g., dexamethasone with either a 5-HT3 receptor antagonist or an NK1 receptor antagonist as well as other drugs as indicated) for prevention of chemotherapy-induced nausea and vomiting (CINV). Withhold Trodelvy doses for Grade 3 nausea or Grade 3-4 vomiting and resume with additional supportive measures when resolved to Grade ≤1. Additional antiemetics and other supportive measures may also be employed as clinically indicated. All patients should be given take-home medications with clear instructions for prevention and treatment of nausea and vomiting.

Increased Risk of Adverse Reactions in Patients with Reduced UGT1A1 Activity: Patients homozygous for the uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1)*28 allele are at increased risk for neutropenia, febrile neutropenia, and anemia and may be at increased risk for other adverse reactions with Trodelvy. The incidence of Grade 3-4 neutropenia was 67% in patients homozygous for the UGT1A1*28, 46% in patients heterozygous for the UGT1A1*28 allele and 46% in patients homozygous for the wild-type allele. The incidence of Grade 3-4 anemia was 25% in patients homozygous for the UGT1A1*28 allele, 10% in patients heterozygous for the UGT1A1*28 allele, and 11% in patients homozygous for the wild-type allele. Closely monitor patients with known reduced UGT1A1 activity for adverse reactions. Withhold or permanently discontinue Trodelvy based on clinical assessment of the onset, duration and severity of the observed adverse reactions in patients with evidence of acute early-onset or unusually severe adverse reactions, which may indicate reduced UGT1A1 function.

Embryo-Fetal Toxicity: Based on its mechanism of action, Trodelvy can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. Trodelvy contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Trodelvy and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with Trodelvy and for 3 months after the last dose.

In the ASCENT study (IMMU-132-05) , the most common adverse reactions (incidence ≥25%) were fatigue, neutropenia, diarrhea, nausea, alopecia, anemia, constipation, vomiting, abdominal pain, and decreased appetite. The most frequent serious adverse reactions (SAR) (>1%) were neutropenia (7%), diarrhea (4%), and pneumonia (3%). SAR were reported in 27% of patients, and 5% discontinued therapy due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the ASCENT study were reduced neutrophils, leukocytes, and lymphocytes.

In the TROPHY study (IMMU-132-06) , the most common adverse reactions (incidence ≥25%) were diarrhea, fatigue, neutropenia, nausea, any infection, alopecia, anemia, decreased appetite, constipation, vomiting, abdominal pain, and rash. The most frequent serious adverse reactions (SAR) (≥5%) were infection (18%), neutropenia (12%, including febrile neutropenia in 10%), acute kidney injury (6%), urinary tract infection (6%), and sepsis or bacteremia (5%). SAR were reported in 44% of patients, and 10% discontinued due to adverse reactions. The most common Grade 3-4 lab abnormalities (incidence ≥25%) in the TROPHY study were reduced neutrophils, leukocytes, and lymphocytes.

UGT1A1 Inhibitors: Concomitant administration of Trodelvy with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38. Avoid administering UGT1A1 inhibitors with Trodelvy.

UGT1A1 Inducers : Exposure to SN-38 may be substantially reduced in patients concomitantly receiving UGT1A1 enzyme inducers. Avoid administering UGT1A1 inducers with Trodelvy.

Please see full Prescribing Information , including BOXED WARNING.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility that various closing conditions for the transaction may not be satisfied or waived; the risk that Gilead may not realize the potential benefits of this transaction; Gilead's ability to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical trials, including those involving Trodelvy; uncertainties relating to regulatory applications for Trodelvy and related filing and approval timelines, including for the treatment of metastatic TNBC, mUC, HR+/HER2- breast cancer, NSCLC, SCLC, head and neck cancer, and endometrial cancer, in the currently anticipated timelines or at all; Gilead's ability to receive regulatory approvals for such indications in a timely manner or at all, including regulatory approvals in Hong Kong, South Korea and Taiwan for metastatic TNBC, and the risk that any such approvals may be subject to significant limitations on use; the possibility that Gilead may make a strategic decision to discontinue development of Trodelvy for such indications and as a result, Trodelvy may never be commercialized for these indications; the risk that physicians may not see the benefits of prescribing Trodelvy; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

U.S. Prescribing Information for Trodelvy including BOXED WARNING , is available at www.gilead.com .

Trodelvy, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company's website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220814005024/en/

Jacquie Ross, Investors investor_relations@gilead.com

Karley Ura, Media Karley.ura@gilead.com

News Provided by Business Wire via QuoteMedia

Trodelvy is the First TROP-2 Directed ADC to Show a Significant Improvement in Overall Survival in HR+HER2- Breast Cancer –

– Planned Second Interim Analysis Demonstrated a Statistically Significant and Clinically Meaningful Benefit for Overall Survival –

Gilead Sciences, Inc. (Nasdaq: GILD) today announced statistically significant and clinically meaningful results from the second interim analysis of the key secondary endpoint of overall survival (OS) in the Phase 3 TROPiCS-02 study evaluating Trodelvy ® (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy. Detailed OS results will be presented at an upcoming medical conference. The safety profile for Trodelvy was consistent with prior studies, and no new safety signals emerged in this patient population.

"These survival results from the TROPiCS-02 study are important for the breast cancer community and we are encouraged by the potential this may have in helping patients who otherwise have limited alternatives," said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences. "We look forward to discussing these results with global health authorities, as pre-treated HR+/HER2- metastatic disease patients currently have limited treatment options and poor quality of life."

Gilead has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug Administration (FDA). These data will also be shared with health authorities outside the U.S.

In June 2022, based on the positive primary results from the TROPiCS-02 study presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, the National Comprehensive Cancer Network ® (NCCN ® ) Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) i included a category 2A preferred recommendation for sacituzumab govitecan-hziy for the investigational use in patients with HR+/HER2- advanced breast cancer after prior treatment including endocrine therapy, a CDK4/6 inhibitor and at least two lines of chemotherapy. The TROPiCS-02 study enrolled HR+/HER2- metastatic breast cancer patients, which included patients with HER2-low and IHC 0 status.

TROPiCS-02 is an event driven study with planned analyses based on a pre-specified number of events. This interim analysis was executed based on the pre-specified criteria.

Trodelvy has not been approved by any regulatory agency for the treatment of HR+/HER2- metastatic breast cancer. Its safety and efficacy have not been established for this indication. Trodelvy has a Boxed Warning for severe or life-threatening neutropenia and severe diarrhea; please see below for additional Important Safety Information.

About HR+/HER2- Breast Cancer

Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer is the most common type of breast cancer and accounts for approximately 70% of all new cases, or nearly 400,000 diagnoses worldwide each year. Almost one in three cases of early-stage breast cancer eventually become metastatic, and among patients with HR+/HER2- metastatic disease, the five-year relative survival rate is 30%. As patients with HR+/HER2- metastatic breast cancer become resistant to endocrine-based therapy, their primary treatment option is limited to single-agent chemotherapy. In this setting, it is common to receive multiple lines of chemotherapy regimens over the course of treatment, and the prognosis remains poor.

The TROPiCS-02 study is a global, multicenter, open-label, Phase 3 study, randomized 1:1 to evaluate Trodelvy versus physicians' choice of chemotherapy (eribulin, capecitabine, gemcitabine, or vinorelbine) in 543 patients with HR+/HER2- metastatic breast cancer who were previously treated with endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy for metastatic disease. The primary endpoint is progression-free survival per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by blinded independent central review (BICR) for participants treated with Trodelvy compared to those treated with chemotherapy. Secondary endpoints include overall survival, overall response rate, clinical benefit rate and duration of response, as well as assessment of safety and tolerability and quality of life measures. In the study, HER2 negativity was defined per American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) criteria as immunohistochemistry (IHC) score of 0, IHC 1+ or IHC 2+ with a negative in-situ hybridization (ISH) test.

More information about TROPiCS-02 is available at https://clinicaltrials.gov/ct2/show/NCT03901339 .

Trodelvy is approved in more than 35 countries, with multiple additional regulatory reviews underway worldwide, for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Trodelvy is also approved in the U.S. under the accelerated approval pathway for the treatment of adult patients with locally advanced or metastatic urothelial cancer (UC) who have previously received a platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.

U.S. Indications for Trodelvy

In the United States, Trodelvy is indicated for the treatment of:

U.S. Important Safety Information for Trodelvy

BOXED WARNING: NEUTROPENIA AND DIARRHEA

UGT1A1 Inducers : Exposure to SN-38 may be substantially reduced in patients concomitantly receiving UGT1A1 enzyme inducers. Avoid administering UGT1A1 inducers with Trodelvy.

Please see full Prescribing Information , including BOXED WARNING.

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead's ability to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional clinical trials, including those involving Trodelvy; uncertainties relating to regulatory applications for Trodelvy and related filing and approval timelines, including with respect to the filing of an sBLA for Trodelvy to expand current indications, and pending or potential applications for the treatment of metastatic TNBC, mUC, HR+/HER2- breast cancer, NSCLC, SCLC, head and neck cancer, and endometrial cancer, in the currently anticipated timelines or at all; Gilead's ability to receive regulatory approvals for such indications in a timely manner or at all, and the risk that any such approvals may be subject to significant limitations on use; the possibility that Gilead may make a strategic decision to discontinue development of Trodelvy for such indications and as a result, Trodelvy may never be commercialized for these indications; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

U.S. Prescribing Information for Trodelvy including BOXED WARNING , is available at www.gilead.com .

Trodelvy, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company's website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

i Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Version 4.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed August 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220814005018/en/

Jacquie Ross, Investors investor_relations@gilead.com

Nathan Kaiser, U.S. Media Nathan.kaiser@gilead.com

Karley Ura, Global Media Karley.ura@gilead.com

News Provided by Business Wire via QuoteMedia

Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.

Oem And Odm Service Avaliable.

Focus On Development And Protection

Has Been Verified Onsite By World-Leading Inspection Company

Boosh Plant-Based Brands Corporate Update

Featured Products

News & Blog

Ohio man dies after getting trapped under industrial printing press - cleveland.com

Drew Barrymore's Kitchenware Line Just Dropped 3 New Items in Contemporary Colors We Love | EatingWell

loading...

Potatoes N' Such Potato Festival

Bismarck's Barnes & Noble Now Open For Business

FORSYTH MARIE - Obituaries - Winnipeg Free Press Passages

Marguerite A Sisti, 75, of Palm Coast, FL passed away peacefully at home on October 28, 2021 surrounded by her loving family. | Palm Coast | Palm Coast Observer

Seven Boston Activities to Break the Ice on a First Date

Lithography Machines and the Chip-Making Process

Paul Daugherty column on fantasy sports and the Big Red Machine